<p>Omeros（纳斯达克代码：OMER - 获取免费报告）于周四发布了季度财报。这家生物制药公司报告本季度每股收益为（$0.19），超出市场共识预期的（$0.58）$0.39，Zacks 报道。</p>
<h2>Omeros 股价上涨 25.3%</h2>
<p>周五午盘交易中，OMER 股票上涨$1.59，达到$7.87。该公司的股票交易量为 4,798,833 股，而其平均交易量为 1,620,257 股。Omeros 的 12 个月最低价为$2.95，最高价为$13.60。该公司的 50 日移动平均价格为$5.71，200 日移动平均价格为$4.59。公司的市值为 5.356 亿美元，市盈率为-3.73，贝塔值为 2.40。</p>
<h2>机构资金流入和流出</h2>
<p>一些机构投资者最近增加或减少了对 OMER 的持股。Acadian Asset Management LLC 在第一季度购买了 Omeros 的新股份，价值$357,000。XTX Topco Ltd 在第二季度购买了 Omeros 的新股份，价值$191,000。Invesco Ltd.在第二季度增加了对 Omeros 的持股 34.1%。Invesco Ltd.目前拥有 116,688 股该生物制药公司的股票，价值$350,000，此前在上个季度又购买了 29,644 股。Marshall Wace LLP 在第二季度将其在 Omeros 的持股增加了 15.1%。Marshall Wace LLP 目前拥有 741,376 股该生物制药公司的股票，价值$2,224,000，此前在该期间又购买了 97,224 股。最后，Sei Investments Co.在第二季度购买了 Omeros 的新股份，价值约$40,000。48.79% 的股票由机构投资者和对冲基金持有。</p>
<h2>华尔街分析师预测增长</h2>
<p>一些研究公司最近对 OMER 发表了看法。Needham &amp; Company LLC 在 10 月 15 日的研究报告中重申了对 Omeros 股票的 “持有” 评级。Wall Street Zen 在 9 月 20 日的研究报告中将 Omeros 的评级从 “卖出” 上调至 “持有”。Weiss Ratings 在 10 月 8 日的报告中重申了对 Omeros 股票的 “卖出（d-）” 评级。D. Boral Capital 在周五的研究报告中重申了 “买入” 评级，并对 Omeros 股票设定了$36.00 的目标价。最后，HC Wainwright 在 10 月 15 日的报告中将 Omeros 的目标价从$9.00 上调至$20.00，并给予该股票 “买入” 评级。一位分析师对该股票给予了强烈买入评级，两位给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “适度买入”，共识目标价为$33.67。</p>
<p><strong>查看我们最新的 OMER 股票报告</strong></p>
<h2>Omeros 公司简介</h2>
<p>（获取免费报告）</p>
<p>Omeros Corporation 是一家临床阶段的生物制药公司，发现、开发和商业化小分子和蛋白质治疗药物，以及针对免疫疾病的孤儿适应症，包括补体介导的疾病、癌症以及成瘾和强迫性障碍。该公司正在开发的产品包括 Narsoplimab（OMS721/MASP-2），该药物已完成针对造血干细胞移植相关血栓性微血管病（TA-TMA）的关键试验；目前正在进行针对免疫球蛋白 A 肾病（IgAN）的第三阶段临床试验；以及针对 COVID-19 的第二阶段临床试验。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票比 Omeros 更好</li>
<li>价值投资：在 2022 年这是一个好策略吗？提示：永远</li>
<li>Jefferies 告诉 NVIDIA 让位，选择 Broadcom 作为顶级半导体股票</li>
<li>NYSE 股票为投资者提供多种优质选择</li>
<li>Fiserv 从未这样做过——这是一个绝对的买入吗？</li>
<li>债券市场假期是什么？如何投资和交易</li>
<li>Eli Lilly 与特朗普达成协议：为什么自那以来股价上涨了 10%</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T01FUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T01FUg"/></p>
<h2>你现在应该投资$1,000 在 Omeros 吗？</h2>
<p>在你考虑 Omeros 之前，你需要听听这个。</p>
<p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每日推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Omeros 并不在名单上。</p>
<p>虽然 Omeros 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

奥麦罗制药

<p>Omeros Corporation 报告了季度收益，超出预期，每股收益为（$0.19），而预期为（$0.58）。股价上涨 25.3%，达到$7.87，交易量增加。机构投资者调整了他们的持股，分析师的评级各不相同，普遍目标价为$33.67。Omeros 开发针对免疫疾病的治疗药物，并推进多个临床试验</p>

<p>Omeros (NASDAQ:OMER - Get Free Report) released its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.58) by $0.39, Zacks reports.</p>
<div class="lb-trans"><p>Omeros（纳斯达克代码：OMER - 获取免费报告）于周四发布了季度财报。这家生物制药公司报告本季度每股收益为（$0.19），超出市场共识预期的（$0.58）$0.39，Zacks 报道。</p>
</div><h2>Omeros Trading Up 25.3%</h2>
<div class="lb-trans"><h2>Omeros 股价上涨 25.3%</h2>
</div><p>OMER stock traded up $1.59 during mid-day trading on Friday, reaching $7.87. The company's stock had a trading volume of 4,798,833 shares, compared to its average volume of 1,620,257. Omeros has a 12 month low of $2.95 and a 12 month high of $13.60. The business's 50 day moving average price is $5.71 and its 200 day moving average price is $4.59. The company has a market cap of $535.60 million, a price-to-earnings ratio of -3.73 and a beta of 2.40.</p>
<div class="lb-trans"><p>周五午盘交易中，OMER 股票上涨$1.59，达到$7.87。该公司的股票交易量为 4,798,833 股，而其平均交易量为 1,620,257 股。Omeros 的 12 个月最低价为$2.95，最高价为$13.60。该公司的 50 日移动平均价格为$5.71，200 日移动平均价格为$4.59。公司的市值为 5.356 亿美元，市盈率为-3.73，贝塔值为 2.40。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>A number of institutional investors have recently added to or reduced their stakes in OMER. Acadian Asset Management LLC bought a new stake in Omeros during the first quarter worth $357,000. XTX Topco Ltd bought a new stake in shares of Omeros during the 2nd quarter worth $191,000. Invesco Ltd. boosted its holdings in shares of Omeros by 34.1% in the 2nd quarter. Invesco Ltd. now owns 116,688 shares of the biopharmaceutical company's stock worth $350,000 after buying an additional 29,644 shares during the last quarter. Marshall Wace LLP grew its position in Omeros by 15.1% during the second quarter. Marshall Wace LLP now owns 741,376 shares of the biopharmaceutical company's stock valued at $2,224,000 after buying an additional 97,224 shares during the period. Finally, Sei Investments Co. purchased a new stake in Omeros during the second quarter worth about $40,000. 48.79% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些机构投资者最近增加或减少了对 OMER 的持股。Acadian Asset Management LLC 在第一季度购买了 Omeros 的新股份，价值$357,000。XTX Topco Ltd 在第二季度购买了 Omeros 的新股份，价值$191,000。Invesco Ltd.在第二季度增加了对 Omeros 的持股 34.1%。Invesco Ltd.目前拥有 116,688 股该生物制药公司的股票，价值$350,000，此前在上个季度又购买了 29,644 股。Marshall Wace LLP 在第二季度将其在 Omeros 的持股增加了 15.1%。Marshall Wace LLP 目前拥有 741,376 股该生物制药公司的股票，价值$2,224,000，此前在该期间又购买了 97,224 股。最后，Sei Investments Co.在第二季度购买了 Omeros 的新股份，价值约$40,000。48.79% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>A number of research firms have recently weighed in on OMER. Needham &amp; Company LLC restated a &#34;hold&#34; rating on shares of Omeros in a research note on Wednesday, October 15th. Wall Street Zen upgraded shares of Omeros from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Saturday, September 20th. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Omeros in a report on Wednesday, October 8th. D. Boral Capital reiterated a &#34;buy&#34; rating and issued a $36.00 price target on shares of Omeros in a research note on Friday. Finally, HC Wainwright upped their target price on Omeros from $9.00 to $20.00 and gave the stock a &#34;buy&#34; rating in a report on Wednesday, October 15th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $33.67.</p>
<div class="lb-trans"><p>一些研究公司最近对 OMER 发表了看法。Needham &amp; Company LLC 在 10 月 15 日的研究报告中重申了对 Omeros 股票的 “持有” 评级。Wall Street Zen 在 9 月 20 日的研究报告中将 Omeros 的评级从 “卖出” 上调至 “持有”。Weiss Ratings 在 10 月 8 日的报告中重申了对 Omeros 股票的 “卖出（d-）” 评级。D. Boral Capital 在周五的研究报告中重申了 “买入” 评级，并对 Omeros 股票设定了$36.00 的目标价。最后，HC Wainwright 在 10 月 15 日的报告中将 Omeros 的目标价从$9.00 上调至$20.00，并给予该股票 “买入” 评级。一位分析师对该股票给予了强烈买入评级，两位给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “适度买入”，共识目标价为$33.67。</p>
</div><p><strong>View Our Latest Stock Report on OMER</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 OMER 股票报告</strong></p>
</div><h2>Omeros Company Profile</h2>
<div class="lb-trans"><h2>Omeros 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.</p>
<div class="lb-trans"><p>Omeros Corporation 是一家临床阶段的生物制药公司，发现、开发和商业化小分子和蛋白质治疗药物，以及针对免疫疾病的孤儿适应症，包括补体介导的疾病、癌症以及成瘾和强迫性障碍。该公司正在开发的产品包括 Narsoplimab（OMS721/MASP-2），该药物已完成针对造血干细胞移植相关血栓性微血管病（TA-TMA）的关键试验；目前正在进行针对免疫球蛋白 A 肾病（IgAN）的第三阶段临床试验；以及针对 COVID-19 的第二阶段临床试验。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Omeros</li>
<li>Value Investing: Is it a Good Strategy in 2022? Hint: Always</li>
<li>Jefferies Tells NVIDIA to Step Aside, Picks Broadcom as Top Semiconductor Stock</li>
<li>NYSE Stocks Give Investors a Variety of Quality Options</li>
<li>Fiserv Has NEVER Done This Before—Is It a Screaming Buy?</li>
<li>What is a Bond Market Holiday? How to Invest and Trade</li>
<li>Eli Lilly Strikes Deal With Trump: Why Shares Are Up 10% Since</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Omeros 更好</li>
<li>价值投资：在 2022 年这是一个好策略吗？提示：永远</li>
<li>Jefferies 告诉 NVIDIA 让位，选择 Broadcom 作为顶级半导体股票</li>
<li>NYSE 股票为投资者提供多种优质选择</li>
<li>Fiserv 从未这样做过——这是一个绝对的买入吗？</li>
<li>债券市场假期是什么？如何投资和交易</li>
<li>Eli Lilly 与特朗普达成协议：为什么自那以来股价上涨了 10%</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T01FUg" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=OMER"/></p>
<h2>Should You Invest $1,000 in Omeros Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Omeros 吗？</h2>
</div><p>Before you consider Omeros, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Omeros 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omeros wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每日推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Omeros 并不在名单上。</p>
</div><p>While Omeros currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Omeros 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

奥麦罗制药（NASDAQ:OMER）公布了财报，每股收益比预期高出 0.39 美元